stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
29.94
0.20
−0.66%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Shares outstanding
Vera Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $64.2M, up 16.1% from $55.3M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $71.8M. Over the past ten years it has ranged from $295.3K (fiscal 2019) to $64.2M (fiscal 2025) — the current reading is the highest in ten years. Vera Therapeutics, Inc. ranks 209th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $64.2M | 16.10% |
| FY2024 | $55.3M | 29.55% |
| FY2023 | $42.7M | 60.73% |
| FY2022 | $26.6M | 97.76% |
| FY2021 | $13.4M | 4,098.66% |
| FY2020 | $320.0K | 8.36% |
| FY2019 | $295.3K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $71.8M | 0.51% |
| Mar 2026 | $71.5M | 11.28% |
| Dec 2025 | $64.2M | 0.61% |
| Sep 2025 | $63.8M | 0.09% |
| 22 more quarters | Free account |
Against its own ten years
Low $295.3K
High $64.2M
Ten-year median
$26.6M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item